Sign up Australia
Proactive Investors - Run By Investors For Investors

Biota Holdings acquires Boston-based drug developer MaxThera Inc

Biota Holdings acquires Boston-based drug developer MaxThera Inc

Australian-based anti-infective drug developer Biota Holdings (ASX:BTA) has acquired the assets and drug development programs of MaxThera, Inc, an antibacterial drug discovery company located in Boston, USA.

As consideration, Biota will pay MaxThera for US$1.2m in cash and US$300,000 in Biota shares.

Shares issued, following completion and will be released from escrow to MaxThera shareholders in two equal tranches at six and twelve months. 

MaxThera shareholders are also entitled to receive twelve percent of all upfront and milestone payments received by Biota if the two main programs are licensed.

MaxThera is a privately owned, antibacterial drug discovery company, developing new classes of drugs directed againstnovel bacterial targets in life threatening infections that are resistant to existing antibiotics.

MaxThera's lead program targets inhibitors of an essential bacterial enzyme in the Coenzyme-A biosynthetic pathway. Coenzyme-A is responsible for a large number of metabolic processes in bacteria.

Biota’s chief executive officer, Peter Cook, said today Biota’s strategy is to increase its portfolio of drugs in development and to expand beyond antivirals into other anti-infectives.

"MaxThera’s portfolio of new targets and novel inhibitor structures are highly complementary to Biota’s own innovative programs,” he said.

Biota will accelerate the development of the lead program and invest up to US$15 million, assuming development milestones are achieved. The investment will be in approximately equal instalments over the next 3 to 5 years.

The majority of the upfront consideration will be expensed in the F2010 financial statements.

Investors may recall Biota has developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.

Subsequent Biota research breakthroughs have included novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim, and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease.

Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

Investors who had acquired Biota shares at the start of the year at just over $0.30, would be looking at tidy gains of over 870%, to the current price of $2.91.





Register here to be notified of future PROAC Company articles
View full PROAC profile View Profile

Proactiveinvestors Timeline

Video
November 23 2016
Newswire
November 23 2016

Related Articles

Bookshelf
October 25 2017
After being rejected by several publishers, Bloomsbury was the one which decided to take a punt on Harry, and what a magical decision it proved to be
picture of text
July 28 2017
Dotdigital has been named as one of the fastest growing companies in Europe
learning symbol on a keyboard
January 17 2017
The English language learning specialist is confident it can kick on in the coming year

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use